TWI721440B - 抗-乙型澱粉樣蛋白抗體及其用途 - Google Patents

抗-乙型澱粉樣蛋白抗體及其用途 Download PDF

Info

Publication number
TWI721440B
TWI721440B TW108118733A TW108118733A TWI721440B TW I721440 B TWI721440 B TW I721440B TW 108118733 A TW108118733 A TW 108118733A TW 108118733 A TW108118733 A TW 108118733A TW I721440 B TWI721440 B TW I721440B
Authority
TW
Taiwan
Prior art keywords
seq
antibody
sequence
cdr2
cdr3
Prior art date
Application number
TW108118733A
Other languages
English (en)
Chinese (zh)
Other versions
TW202033549A (zh
Inventor
謝奉勳
徐祖安
全 石
沈三泰
Original Assignee
財團法人國家衛生研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 財團法人國家衛生研究院 filed Critical 財團法人國家衛生研究院
Publication of TW202033549A publication Critical patent/TW202033549A/zh
Application granted granted Critical
Publication of TWI721440B publication Critical patent/TWI721440B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW108118733A 2018-05-30 2019-05-30 抗-乙型澱粉樣蛋白抗體及其用途 TWI721440B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862678080P 2018-05-30 2018-05-30
US62/678,080 2018-05-30

Publications (2)

Publication Number Publication Date
TW202033549A TW202033549A (zh) 2020-09-16
TWI721440B true TWI721440B (zh) 2021-03-11

Family

ID=68694402

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108118733A TWI721440B (zh) 2018-05-30 2019-05-30 抗-乙型澱粉樣蛋白抗體及其用途

Country Status (8)

Country Link
US (1) US11084873B2 (https=)
EP (1) EP3801618A4 (https=)
JP (1) JP7210612B2 (https=)
KR (1) KR102523019B1 (https=)
CN (1) CN112601550B (https=)
CA (1) CA3100896C (https=)
TW (1) TWI721440B (https=)
WO (1) WO2019231957A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102112492A (zh) * 2007-11-14 2011-06-29 株式会社未来创药研究所 使用抗gpr49抗体的癌症的诊断和治疗
CN102574915A (zh) * 2009-08-06 2012-07-11 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
US20120288896A1 (en) * 2005-12-12 2012-11-15 Ac Immune S.A. Nucleic acid molecules encoding anti-amyloid-beta antibodies
CN106488774A (zh) * 2014-04-18 2017-03-08 纽约州立大学研究基金会 人源化抗‑tf‑抗原抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102368C2 (ru) * 2005-12-12 2013-07-10 Ас Иммуне С.А. СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ β-АМИЛОИДА 1-42 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ ИМЕЮТ ТЕРАПЕВТИЧЕСКИЕ СВОЙСТВА
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
WO2009033743A1 (en) * 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
DK2207568T3 (en) * 2007-11-16 2017-09-18 Univ Rockefeller ANTIBODIES SPECIFIC TO THE PROTOFIBRILE FORM OF BETA AMYLOID PROTEIN
CN105979962A (zh) 2012-12-07 2016-09-28 比奥根国际神经科学公司 使用抗Aβ抗体减少脑淀粉样蛋白斑块的方法
US9879076B2 (en) * 2013-03-15 2018-01-30 Ramot At Tel Aviv University Ltd. Methods and compositions with immune therapy for treatment of dementia
US10772969B2 (en) * 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
DK3430397T3 (da) * 2016-03-14 2022-05-02 Biogen Int Neuroscience Gmbh Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120288896A1 (en) * 2005-12-12 2012-11-15 Ac Immune S.A. Nucleic acid molecules encoding anti-amyloid-beta antibodies
CN102112492A (zh) * 2007-11-14 2011-06-29 株式会社未来创药研究所 使用抗gpr49抗体的癌症的诊断和治疗
CN102574915A (zh) * 2009-08-06 2012-07-11 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
CN106488774A (zh) * 2014-04-18 2017-03-08 纽约州立大学研究基金会 人源化抗‑tf‑抗原抗体

Also Published As

Publication number Publication date
KR102523019B1 (ko) 2023-04-18
AU2019277171A1 (en) 2020-12-03
CN112601550A (zh) 2021-04-02
EP3801618A1 (en) 2021-04-14
JP2021525512A (ja) 2021-09-27
JP7210612B2 (ja) 2023-01-23
CA3100896A1 (en) 2019-12-05
TW202033549A (zh) 2020-09-16
US20190367593A1 (en) 2019-12-05
CA3100896C (en) 2023-08-29
WO2019231957A1 (en) 2019-12-05
KR20210041535A (ko) 2021-04-15
US11084873B2 (en) 2021-08-10
EP3801618A4 (en) 2022-07-27
CN112601550B (zh) 2023-12-08

Similar Documents

Publication Publication Date Title
RU2644242C2 (ru) Гуманизированное тау-антитело
KR102508933B1 (ko) 알파-시누클레인에 대한 항체 및 그 용도
AU2013302540B2 (en) Methods of treating a tauopathy
CA2812865C (en) Phosphospecific antibodies recognising tau
JP7357834B2 (ja) アミロイドベータに対する抗体
JP6261621B2 (ja) アルファ−シヌクレイン抗体及びその使用
US9216217B2 (en) Oligomer-specific amyloid beta epitope and antibodies
KR20100097651A (ko) 베타-아밀로이드 펩티드에 특이적인 신규 항체 및 진단제 또는 진단약으로서의 그 용도
AU2016353553A1 (en) Amyloid beta epitopes and antibodies thereto
TWI721440B (zh) 抗-乙型澱粉樣蛋白抗體及其用途
KR20230039734A (ko) 항-Aβ 항체
US20230141177A1 (en) Antibodies to misfolded amyloid beta
CN116249717A (zh) 识别分拣蛋白的抗体
US12351623B2 (en) Antibody compositions targeting non-phosphorylated alpha-synuclein aggregates
JP2023086132A (ja) アミロイドベータに対する抗体
WO2016092865A1 (ja) アミロイドβの２２位及び２３位のターン構造を極めて特異的に認識する抗体
JP2026503664A (ja) 抗ａベータ抗体を用いた神経障害の治療方法
HK40040248A (en) Anti-abeta antibodies and uses thereof
HK40040248B (zh) 抗-乙型淀粉样蛋白抗体及其用途
AU2022377057A1 (en) Anti-amyloid beta antibodies and methods of using the same